Loading stock data…
CSTL
$24.71+0.11 (+0.45%)
Market OpenUpdated 10:10 AM EDT
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Castle Biosciences, Inc. in the Healthcare sector is trading at $24.71. The stock is currently 44% below its 52-week high of $44.28, remaining 13.4% below its 200-day moving average. Technical signals show neutral RSI of 51 and bullish MACD crossover, explaining why CSTL maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 51) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$24.71
Potential Upside
5%
Whystock Fair Value$25.95
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$760.43M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.19
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-2.01%
Volume
Today's trading volume
33,539
Recent News
BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance Raised
BMRN misses Q1 EPS estimates despite a revenue beat, as charges and higher costs weigh on profits, while new Amicus deal lifts the 2026 outlook.
Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in Focus
KRYS shares jump after a Q1 beat as Vyjuvek fuels 32% revenue growth, strong uptake and global expansion, with pipeline catalysts lined up through 2026.
AXSM Q1 Loss Widens, Revenues Jump on Higher Auvelity Sales
Axsome posts a wider Q1 loss but revenues jump 57%, driven by strong Auvelity and Sunosi sales.
Wall Street Analysts Predict an 85.15% Upside in Castle Biosciences (CSTL): Here's What You Should Know
The mean of analysts' price targets for Castle Biosciences (CSTL) points to an 85.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss Estimates
CRSP posts a wider Q1 loss and revenues miss, pressuring shares, even as Casgevy sales grow and cash reserves strengthen from recent financing.